Nanjing Vishee Medical Technology Co Ltd (688580) - Total Assets

Latest as of March 2026: CN¥1.86 Billion CNY ≈ $272.61 Million USD

Based on the latest financial reports, Nanjing Vishee Medical Technology Co Ltd (688580) holds total assets worth CN¥1.86 Billion CNY (≈ $272.61 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See today's stock price for Nanjing Vishee Medical Technology Co Ltd for real-time trading data and today's change.

Nanjing Vishee Medical Technology Co Ltd - Total Assets Trend (2013–2025)

This chart illustrates how Nanjing Vishee Medical Technology Co Ltd's total assets have evolved over time, based on quarterly financial data. Also see 688580 cash generation efficiency for how efficiently the company converts equity into cash flow.

Nanjing Vishee Medical Technology Co Ltd - Asset Composition Analysis

Current Asset Composition (December 2025)

Nanjing Vishee Medical Technology Co Ltd's total assets of CN¥1.86 Billion consist of 58.4% current assets and 41.6% non-current assets.

Asset Category Amount (CNY) % of Total Assets
Cash & Equivalents CN¥0.00 53.6%
Accounts Receivable CN¥17.10 Million 0.9%
Inventory CN¥42.21 Million 2.2%
Property, Plant & Equipment CN¥0.00 0.0%
Intangible Assets CN¥130.37 Million 6.8%
Goodwill CN¥69.31 Million 3.6%

Asset Composition Trend (2013–2025)

This chart illustrates how Nanjing Vishee Medical Technology Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore 688580 working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Nanjing Vishee Medical Technology Co Ltd's current assets represent 58.4% of total assets in 2025, a decrease from 93.4% in 2013.
  • Cash Position: Cash and equivalents constituted 53.6% of total assets in 2025, up from 11.0% in 2013.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 9.0% of total assets, an increase from 1.0% in 2013.
  • Asset Diversification: The largest asset category is intangible assets at 6.8% of total assets.

Nanjing Vishee Medical Technology Co Ltd Competitors by Total Assets

Key competitors of Nanjing Vishee Medical Technology Co Ltd based on total assets are shown below.

Company Country Total Assets
Shenzhen New Industries Biomedical
SHE:300832
China CN¥9.58 Billion
COCHLEAR LTD ADR 1/2/O.N.
F:OC50
Germany €2.83 Billion
Establishment Labs Holdings Inc
NASDAQ:ESTA
USA $351.93 Million
SonoScape Medical Corp
SHE:300633
China CN¥4.30 Billion
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317
China CN¥3.71 Billion
Guangdong Transtek Medical Electronics Co Ltd
SHE:300562
China CN¥1.42 Billion
Paxman AB
ST:PAX
Sweden Skr487.65 Million
Affluent Medical SAS
PA:AFME
France €59.84 Million

Nanjing Vishee Medical Technology Co Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 9.65 7.58 12.82
Quick Ratio 9.31 7.34 12.51
Cash Ratio 0.00 0.00 0.00
Working Capital CN¥925.23 Million CN¥1.00 Billion CN¥1.26 Billion

Nanjing Vishee Medical Technology Co Ltd - Advanced Valuation Insights

This section examines the relationship between Nanjing Vishee Medical Technology Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 2.73
Latest Market Cap to Assets Ratio 0.35
Asset Growth Rate (YoY) 4.9%
Total Assets CN¥1.91 Billion
Market Capitalization $676.05 Million USD

Valuation Analysis

Below Book Valuation: The market values Nanjing Vishee Medical Technology Co Ltd's assets below their book value (0.35x), which may indicate investor concerns about asset quality or future growth.

Positive Asset Growth: Nanjing Vishee Medical Technology Co Ltd's assets grew by 4.9% over the past year, showing continued investment in the company's operational capacity.

Annual Total Assets for Nanjing Vishee Medical Technology Co Ltd (2013–2025)

The table below shows the annual total assets of Nanjing Vishee Medical Technology Co Ltd from 2013 to 2025.

Year Total Assets Change
2025-12-31 CN¥1.91 Billion
≈ $279.35 Million
+4.87%
2024-12-31 CN¥1.82 Billion
≈ $266.38 Million
+0.79%
2023-12-31 CN¥1.81 Billion
≈ $264.28 Million
+7.23%
2022-12-31 CN¥1.68 Billion
≈ $246.45 Million
+2.77%
2021-12-31 CN¥1.64 Billion
≈ $239.80 Million
+6.38%
2020-12-31 CN¥1.54 Billion
≈ $225.42 Million
+281.09%
2019-12-31 CN¥404.22 Million
≈ $59.15 Million
+31.09%
2018-12-31 CN¥308.36 Million
≈ $45.12 Million
+25.06%
2017-12-31 CN¥246.57 Million
≈ $36.08 Million
+45.29%
2016-12-31 CN¥169.71 Million
≈ $24.83 Million
+33.90%
2015-12-31 CN¥126.74 Million
≈ $18.55 Million
+55.82%
2014-12-31 CN¥81.34 Million
≈ $11.90 Million
+13.77%
2013-12-31 CN¥71.50 Million
≈ $10.46 Million
--

About Nanjing Vishee Medical Technology Co Ltd

SHG:688580 China Medical Devices
Market Cap
$676.05 Million
CN¥4.62 Billion CNY
Market Cap Rank
#10809 Global
#2931 in China
Share Price
CN¥48.24
Change (1 day)
-4.36%
52-Week Range
CN¥43.34 - CN¥69.70
All Time High
CN¥207.27
About

Nanjing Vishee Medical Technology Co., Ltd provides rehabilitation meditation products and solutions in China and internationally. The company offers MagNeuro, a transcranial magnetic stimulation (TMS) device, and MagNeuro ONE, a TMS therapy system with navigation for psychiatric and neurological applications. It also provides MagBelle, a pelvic floor muscle stimulator for the treatment of urinar… Read more